Laboratory for Brain and Neurocognitive Development, Department of Psychology, Institution of Humanities, Ural Federal University, Yekaterinburg, Russia.
Faculty of General Medicine, Ural State Medical University, Yekaterinburg, Russia.
Medicine (Baltimore). 2023 Jul 7;102(27):e34105. doi: 10.1097/MD.0000000000034105.
Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116.
A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies.
The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms.
Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients.
最近的试验强调了口服抗病毒药物 VV116 在治疗轻症 COVID-19 患者方面的潜力。然而，尚无综合研究评估 VV116 的安全性和疗效。因此，我们进行了一项系统评价，以评估 VV116 的安全性和疗效。
在 PubMed、Scopus 和 Google Scholar 网站上进行了全面检索，截止日期为 2023 年 3 月 23 日，以确定相关研究。
纳入的 3 项研究结果表明，VV116 实验组未报告严重不良事件，病毒脱落时间比对照组快 2.57 天，在缓解主要症状方面与奈玛特韦-利托那韦对照组相当。
综合来看，现有研究表明 VV116 具有可靠的安全性和疗效。然而，试验数量有限，无法进行荟萃分析，且纳入人群为轻症和中度症状的年轻个体，不包括 COVID-19 重症患者。我们希望未来能开展更多研究，以确保 VV116 在临床环境中具有更可靠的安全性和疗效，特别是在重症或危重症患者中。
